Global Psychiatry Partnering 2010-2015: Deal trends, players and financials

Date: June 1, 2015
Pages: 700
Price:
US$ 2,995.00
License [?]:
Publisher: CurrentPartnering
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), CD-ROM Mail Delivery, E-mail Delivery (Word)
ID: P6E2A7ABEC3EN
Leaflet:

Download PDF Leaflet

Global Psychiatry Partnering 2010-2015: Deal trends, players and financials
Summary

The Global Psychiatry Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the psychiatry partnering deals and agreements entered into by the worlds leading healthcare companies.

Description

The Global Psychiatry Partnering 2010-2015 report provides an understanding and access to the psychiatry partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in psychiatry partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Psychiatry partnering contract documents
  • Top psychiatry deals by value
The Global Psychiatry Partnering 2010-2015 report provides an understanding and access to the psychiatry partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter psychiatry partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors psychiatry technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest psychiatry agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all psychiatry partnering deals announced since 2010 including financial terms where available including over 600 links to online deal records of actual psychiatry partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of the report provide an orientation of psychiatry dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in psychiatry deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.

A popular section with readers; chapter 3 covers the average financial deal terms for deals signed in the psychiatry field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.

Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in psychiatry partnering and dealmaking since 2010.

Chapter 4 covers the leading psychiatry deals that have been announced over the past five years. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Full deal contract documents where available for each deal are indicated by a yes/no symbol. Within this chapter the most active psychiatry deal makers are also listed as well as the deal making activities and the number of deals entered into by the big pharma and biotech companies.

Chapter 5 acts as a contracts reference directory chapter providing a full comprehensive and detailed list of the psychiatry partnering deals signed and announced since January 2010. This chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. In order for readers to view full details of each agreement the report is formatted so that each deal title links via Weblink to an online version of the actual deal at Current Agreements (www.currentagreements.com) deals and alliances database.

In conclusion, this report gives prospective dealmakers a thorough overview of all the deals announced in the psychiatry field preparing them with everything they need to know about partnering in the research, development and commercialization of psychiatry technologies and products.

A full appendix is provided at the very end of the report which lists all the psychiatry deals announced since 2010 categorized by company A-Z, deal type, stage of development, technology and therapy. Where available contract documents are supplied, these documents include additional deal information in comparison to only the brief summary that is provided through a press release. Readers can analyze the contracts fully by reviewing the detailed terms between the parties under which monies and licensing rights are exchanged. The appendix is useful for looking at all the deals signed by one specific company.

Report scope

Global Psychiatry Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to psychiatry trends and structure of deals entered into by leading companies worldwide.

Global Psychiatry Partnering 2010-2015 includes:
  • Trends in psychiatry dealmaking in the biopharma industry since 2010
  • Analysis of psychiatry deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 600 psychiatry deal records
  • The leading psychiatry deals by value since 2010
In Global Psychiatry Partnering 2010-2015, the available deals are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Psychiatry Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 600 psychiatry deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
Benefits

Global Psychiatry Partnering 2010-2015 report provides the reader with the following key benefits:
  • In-depth understanding of psychiatry deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 600 psychiatry deals entered into by the world’s biopharma companies
  • Detailed access to actual psychiatry contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a psychiatry agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary

CHAPTER 1 – INTRODUCTION

CHAPTER 2 – TRENDS IN PSYCHIATRY DEALMAKING

2.1. Introduction
2.2. Psychiatry partnering over the years
2.3. Psychiatry partnering by deal type
2.4. Psychiatry partnering by industry sector
2.5. Psychiatry partnering by stage of development
2.6. Partnering by psychiatry specific technology type

CHAPTER 3 – AVERAGE FINANCIAL DEAL TERMS FOR PSYCHIATRY PARTNERING

3.1. Introduction
3.2. Disclosed financials terms for psychiatry partnering
3.3 Psychiatry partnering headline values
3.4 Psychiatry deal upfront payments
3.5 Psychiatry deal milestone payments
3.6 Psychiatry royalty rates

CHAPTER 4 – LEADING PSYCHIATRY DEALS

4.1. Introduction
4.1. Most active in psychiatry partnering
4.2. Top psychiatry deals by value
4.3. Big pharma psychiatry dealmaking activity
4.4. Big biotech psychiatry dealmaking activity

CHAPTER 5 – PSYCHIATRY CONTRACTS DIRECTORY

5.1. Introduction
5.2. Psychiatry partnering by company A-Z
5.3. Psychiatry partnering stage of development
5.4. Psychiatry partnering by deal type
5.6. Psychiatry partnering by technology type

APPENDICES

Introduction
Appendix 1 – Directory of psychiatry deals by company A-Z 2010-2015*
Appendix 2 – Directory of psychiatry deals by stage of development 2010-2015
Appendix 3 – Directory of psychiatry deals by deal type 2010-2015
Appendix 4 – Directory of psychiatry deals by therapy area 2010-2015
Appendix 5 – Orphan disease partnering resource center

ABOUT WILDWOOD VENTURES

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Reports

TABLE OF FIGURES

Figure 1: Psychiatry partnering since 2010
Figure 2: Psychiatry partnering by deal type since 2010
Figure 3: Psychiatry partnering by industry sector since 2010
Figure 4: Psychiatry partnering by stage of development since 2010
Figure 5: Psychiatry partnering by disease type since 2010
Figure 6: Psychiatry partnering by specific technology type since 2010
Figure 7: Psychiatry deals with a headline value – by stage of development
Figure 8: Psychiatry deals with upfront payment values – by stage of development
Figure 9: Psychiatry deals with milestone payment – by stage of development
Figure 10: Psychiatry deals with royalty rates
Figure 11: Active psychiatry dealmaking activity– 2010 to 2015
Figure 12: Top psychiatry deals by value since 2010
Figure 13: Big pharma – top 50 – psychiatry deals 2010 to 2015
Figure 14: Big pharma psychiatry deal frequency – 2010 to 2015
Figure 15: Big biotech – top 50 – psychiatry deals 2010 to 2015
Figure 16: Big biotech psychiatry deal frequency – 2010 to 2015
Figure 17: Online partnering resources
Figure 18: Forthcoming partnering events
Skip to top


Pharmacogenomics Partnering Terms and Agreements US$ 1,995.00 Nov, 2014 · 455 pages
Bioinformatics Partnering Terms and Agreements US$ 2,995.00 Oct, 2014 · 1268 pages
Antibody Partnering Terms and Agreements US$ 2,995.00 Jan, 2015 · 1625 pages
Biomarker Partnering Terms and Agreements US$ 2,995.00 Nov, 2014 · 1048 pages

Ask Your Question

Global Psychiatry Partnering 2010-2015: Deal trends, players and financials
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: